A randomized controlled trial of coenzyme Q10 for fatigue in the late-onset sequelae of poliomyelitis
MetadataShow full item record
Objective: To determine if coenzyme Q10 alleviates fatigue in the late-onset sequelae of poliomyelitis. Design: Parallel-group, randomized, placebo-controlled trial. Background setting: Coenzyme Q10 has been shown to boost muscle energy metabolism in post-polio subjects but it does not promote muscle strength, endurance or function in polio survivors with postpoliomyelitis syndrome. However, the collective increased energy metabolism might contribute to a reduction in post-polio fatigue. Participants: Polio survivors from theAustralian post-polio networks in Queensland and New SouthWales who attribute a moderate to high level of fatigue to their diagnosed late-onset sequelae of poliomyelitis. Those withfatigue-associated comorbidities of diabetes, anaemia,hypothyroidismandfibromyalgia were excluded. Method: Participants were assigned (1:1), with stratification ofthose who use energy-savingmobility aids, to receive 100 mg coenzyme Q10 or matching placebo daily for 60 days. Participants and investigators were blinded to group allocation. Fatigue was assessed by the Multidimensional Assessment of Fatigue as the primary outcome and the Fatigue Severity Scale as secondary outcome. Results: Of 103 participants, 54 were assigned to receive coenzyme Q10 and 49 to receive the placebo. The difference in the mean score reductions between the two groups was not statistically significant for either fatigue measure. Oral supplementation with coenzyme Q10 was safe and well-tolerated. Conclusion:Adaily dose of 100 mg coenzyme Q10 for 60 days does not alleviate the fatigue ofthe late-onset sequelae of poliomyelitis.
Complementary Therapies in Medicine
Complementary and Alternative Medicine not elsewhere classified